Data Year:
Select Other Years

For its 2024 fiscal year, NIAGEN BIOSCIENCE INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Robert Fried
Chief Executive Officer
Total Compensation $1,212,131 View details Pay Rank By Title In Biotechnology industry #576 View more
Brianna Gerber
Former Chief Financial Officer
Total Compensation $450,969 View details Pay Rank By Title In Biotechnology industry #539 View more
James Lee
Controller, Former Interim Chief Financial Officer
Total Compensation $374,470 View details Pay Rank By Title In Biotechnology industry #561 View more
Carlos Lopez
SVP, General Counsel
Total Compensation $347,638 View details Pay Rank By Title In Biotechnology industry #84 View more
Ozan Pamir
Chief Financial Officer
Total Compensation $461,641 View details Pay Rank By Title In Biotechnology industry #534 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at NIAGEN BIOSCIENCE INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. NIAGEN BIOSCIENCE INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. NIAGEN BIOSCIENCE INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Robert Fried
Chief Executive Officer
Total Cash $786,497 Equity $424,898 Other $736 $1,212,131
Brianna Gerber
Former Chief Financial Officer
Total Cash $215,000 Equity $227,445 Other $8,524 $450,969
James Lee
Controller, Former Interim Chief Financial Officer
Total Cash $277,895 Equity $87,979 Other $8,596 $374,470
Carlos Lopez
SVP, General Counsel
Total Cash $185,183 Equity $159,928 Other $2,527 $347,638
Ozan Pamir
Chief Financial Officer
Total Cash $102,274 Equity $357,869 Other $1,498 $461,641
For its 2024 fiscal year, NIAGEN BIOSCIENCE INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Robert Fried CEO Pay $1,212,131 Median Employee Pay $130,524 CEO Pay Ratio 9:1
For its 2024 fiscal year, NIAGEN BIOSCIENCE INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Ann Cohen Total Cash $103,819
Frank Jaksch, Jr. Total Cash $106,319
Gary Ng Total Cash $83,819
Hamed Shahbazi Total Cash $81,319
Kristin Patrick Total Cash $96,319
Steven Rubin Total Cash $131,319
Wendy Yu Total Cash $81,319
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.